Coassembly Nanomedicine Mediated by Intermolecular Interactions Between Methotrexate and Baricitinib for Improved Rheumatoid Arthritis Treatment.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38437640.
- Also identified by DOI 10.1021/acsnano.3c12692.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The combination of anti-rheumatoid arthritis (RA) drugs methotrexate (MTX) and baricitinib (BTN) has been reported to improve RA treatment efficacy. However, study on the strategy of combination is elusive when considering the benefit of the synergy between MTX and BTN. In this study, we found that the N-heterocyclic rings in the MTX and BTN offer hydrogen bonds and π-π stacking interactions, driving the formation of exquisite vesicular morphology of nanovesicles, denoted as MB NVs. The MB NVs with the MTX/BTN weight ratio of 2:1, MB NVs (2:1), showed an improved anti-RA effect through the synergy between the anti-inflammatory and antiproliferative responses. This work presents that the intermolecular interactions between drug molecules could mediate the coassembly behavior into nanomedicine as well as the therapy synergy both <i>in vitro</i> and <i>in vivo</i>, which may provide further understanding on the rational design of combination nanomedicine for therapeutic purposes.
Medical subject headings
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Azetidines
- Purines
- Pyrazoles
- Sulfonamides